^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CXCR5 (C-X-C Motif Chemokine Receptor 5)

    i
    Other names: CXCR5, C-X-C Motif Chemokine Receptor 5, MDR15, Burkitt Lymphoma Receptor 1, GTP Binding Protein (Chemokine (C-X-C Motif) Receptor 5), Burkitt Lymphoma Receptor 1, GTP-Binding Protein, Chemokine (C-X-C Motif) Receptor 5, C-X-C Chemokine Receptor Type 5, Monocyte-Derived Receptor 15, MDR-15, CD185, BLR1, Burkitt Lymphoma Receptor 1, CD185 Antigen
    23d
    The role of sleep deprivation in prostate cancer and a preliminary exploration of its mechanisms. (PubMed, Pathol Res Pract)
    In summary, our findings suggest that sleep deprivation may accelerate prostate cancer progression by activating the CXCL13/CXCR5/JNK signaling axis. These results provide preliminary insights into a potential therapeutic direction.
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    24d
    Chemokine Networks in Cutaneous T Cell Lymphoma: Tumor Microenvironment Remodeling and Therapeutic Targets. (PubMed, Curr Issues Mol Biol)
    Therapeutically, agents targeting chemokine pathways, most notably the CCR4 monoclonal antibody Mogamulizumab, have demonstrated clinical efficacy, while emerging inhibitors of CCR6, CCR5, and CXCR4 offer promising avenues for intervention. We further highlight how recent single-cell and other high-dimensional omics studies refine cell-type-specific chemokine sources and receptor expression, enabling more precise mapping of chemokine-driven intercellular communication programs in CTCL TME remodeling and better prioritization of therapeutic targets and biomarkers.
    Review • Journal • IO biomarker
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CCR4 (C-C Motif Chemokine Receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD4 (CD4 Molecule) • CCL19 (C-C Motif Chemokine Ligand 19) • CCR7 (Chemokine (C-C motif) receptor 7) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL21 (C-C Motif Chemokine Ligand 21) • CCL22 (C-C Motif Chemokine Ligand 22) • CCL27 (C-C Motif Chemokine Ligand 27) • CCR2 (C-C Motif Chemokine Receptor 2) • CCR8 (C-C Motif Chemokine Receptor 8) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • CCR6 (C-C Motif Chemokine Receptor 6)
    |
    Poteligeo (mogamulizumab-kpkc)
    28d
    C-X-C motif chemokine ligand 13 suppresses osteoclast differentiation via interference with RANKL-RANK interaction. (PubMed, Front Immunol)
    Mechanistically, CXCL13 attenuated MAPK and NF-κB activation and blocked p65 nuclear translocation in a CXCR5-independent manner by competitively interfering with RANKL-RANK binding and downstream RANK-TRAF6 signaling. These findings identify CXCL13 as a novel suppressor of osteoclastogenesis by interfering with RANKL-RANK signaling, unveiling an unrecognized regulatory role in osteoclast biology and suggesting potential therapeutic relevance for bone loss disorders.
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • CASP3 (Caspase 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • TRAF6 (TNF Receptor Associated Factor 6)
    1m
    CXCR3/CXCL10 Axis-Mediated T Cell Infiltration in the Lungs of Patients With HTLV-1-Associated Diseases: Implications for Subclinical Pulmonary Involvement. (PubMed, J Med Virol)
    Histology revealed CD3+ mononuclear cell infiltration in alveolar septa and peribronchiolar regions in HAB and HAM, consistent with T cell-mediated alveolitis and bronchiolitis, and CXCL10 expression was elevated in infiltrated lesions. Collectively, these findings implicate the CXCR3/CXCL10 axis as a common pathway for pulmonary T cell recruitment in HTLV-1-associated diseases.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CCR4 (C-C Motif Chemokine Receptor 4) • CD4 (CD4 Molecule) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    1m
    Stereotactic Body Radiation Therapy With Pembrolizumab in PD-1 Inhibitor Refractory, Recurrent or Metastatic, Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial. (PubMed, Int J Radiat Oncol Biol Phys)
    In anti PD-1-refractory R/M HNSCC, SBRT with pembrolizumab was safe and feasible, suggesting activity when all progressing lesions were treated. Immune profiling describes pre-existing memory T and B cell phenotypes that appear to correlate with treatment benefit. These findings support further study and clinical use of comprehensive SBRT plus PD-1 blockade in this hard-to-treat population.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • TRB (T Cell Receptor Beta Locus)
    |
    Keytruda (pembrolizumab)
    2ms
    CCL18: a potential immunosuppressive biomarker for prognosis in ABC diffuse large B-cell lymphoma. (PubMed, Front Immunol)
    We validated MAPK10 promoter hypermethylation and CCL18 overexpression as prognostic biomarkers in ABC DLBCL. These findings, derived from integrative transcriptomic and immunogenomic profiling, provide clinically relevant insights into disease biology and support biomarker-guided strategies for precision treatment in aggressive B-cell lymphomas.
    Journal
    |
    CD8 (cluster of differentiation 8) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • MMP9 (Matrix metallopeptidase 9) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • CCL18 (C-C Motif Chemokine Ligand 18) • MAPK10 (Mitogen-Activated Protein Kinase 10)
    |
    nCounter® PanCancer Immune Profiling Panel
    2ms
    Emerging involvement of CXCL13 in cancer development and progression. (PubMed, Cytokine Growth Factor Rev)
    We further examine how CXCL13-CXCR5 signaling contributes to aquisition of cancer hallmarks, mainly through angiogenesis, epithelial-mesenchymal transition, metastatic niche conditioning, and the formation of tertiary lymphoid structures that influence antitumor immunity. By integrating biochemical, structural, and immunological insights, this review highlights the CXCL13-CXCR5 axis as a critical interface between lymphoid neogenesis and tumor evolution, and as a potential target for therapeutic modulation in cancer.
    Review • Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    3ms
    Enzyme-Activatable CXCL13 Chemokine Probes Enable Direct Fluorescence Detection of Hypoxic Subpopulations of Human B Cells. (PubMed, J Am Chem Soc)
    Notably, we demonstrated that hCXCL13-6 enables direct identification of hypoxic B cells in cell mixtures derived from human blood biosamples. The combination of 'clickable' fluorogenic reporters with nonperturbative ligation to chemokine proteins will create new avenues for the rational design of targeted B cell probes to study inflammatory diseases and hematological malignancies.
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    3ms
    Expression of CXCL13 in clear cell renal cell carcinoma: Assisting clinical diagnosis and exploring the malignant biological mechanism. (PubMed, Biochem Biophys Res Commun)
    The CXCL13/CXCR5 axis activates the NF-κB signaling pathway through an autonomous effect in ccRCC, theoretically suggesting the formation of a positive feedback loop that drives tumor malignant progression. CXCL13 may serve as a biomarker for ccRCC and a highly promising therapeutic target.
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • NFKBIA (NFKB Inhibitor Alpha 2)
    3ms
    The expression and significance of CXCL13 and CXCR5 in the tumor microenvironment of primary central nervous system diffuse large B-cell lymphoma. (PubMed, Free Radic Biol Med)
    We analyze the correlation between CXCL13/CXCR5 and the infiltration of immune cells (T cells, macrophages), the expression of immune checkpoints (PD-L1, CD39). The CXCL13/ CXCR5 axis may exert a bidirectional regulatory effect of anti-tumor immunity and tumor immune evasion through multiple mechanisms, such as influencing the infiltration of immune cells, the expression of immune checkpoints, and the immune function of the peripheral blood, which ultimately affects the therapeutic efficacy and prognosis of PCNS-DLBCL.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    3ms
    Single-cell and spatial transcriptomics implicate a prognostic function of tertiary lymphoid structures in gastric cancer. (PubMed, Nat Commun)
    Multimodal cell-cell interaction analysis and functional experiments demonstrate that HEV expressed VCAM1 and ICAM1 recruits and activates CXCL13+ TLC through the CXCL13-ACKR1 pathway, which promotes TLS formation via CXCL13-CXCR5-dependent crosstalk with B lymphocytes. We further develop a single-cell/spatial TLS signature that captures the cellular ecosystem of iTLS-containing tumor, demonstrating predictive value for immunotherapy outcomes in GC patients.
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICAM1 (Intercellular adhesion molecule 1) • LAMP3 (Lysosomal Associated Membrane Protein 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • VCAM1 (Vascular Cell Adhesion Molecule 1) • CD80 (CD80 Molecule) • SELP (Selectin P) • ACKR1 (Atypical Chemokine Receptor 1)